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Introduction
Diet and nutrition are important factors in the promotion and
maintenance of good health throughout the entire life course.
Their role as determinants of chronic disease is well established
and they therefore occupy a prominent position in global
disease prevention activities (1). Alzheimer's disease (AD) and
other dementias are among the most burdensome age-related
chronic diseases. Thus, risk management strategies are urgently
needed to tackle the growing burden of cognitive decline in the
elderly.
Nutritional status has been implicated as one of the many
potential risk factors for cognitive decline in elderly people.
Nutritional interventions are of interest because they are usually
safe, relatively inexpensive in comparison to pharmacologic
intervention, and provide some unique opportunities for long-
term use. A Task Force on designing trials of nutritional
intervention for cognitive decline in older adults was held in
Toulouse in September 2012. The aim of the Task Force was to
bring together a limited number of leading experts from
academia, the food industry, and regulatory agencies to
determine the best trial designs for identifying nutritional
interventions that would enable us to reach our goal of
maintaining or improving cognitive function with aging. Like
trials of pharmacologic interventions, nutritional studies require
clarity of rationale, appropriately selected trial designs, and
rigorously applied statistical analysis. However, different types
of data may be required to establish the impact of foods or
supplements on cognition.  The objective of this report is to
provide an overview of the current landscape in the field and
provide a summary of the discussion and outcomes of the
meeting. Ultimately, the Task Force hopes to establish specific
recommendations that will expedite the development of
nutritional interventions in the elderly population.
The role of food in maintaining or improving cognitive
functions with age
AD is the most frequent cause of dementia in older persons.
The main risk factors for late-onset AD (i.e., age and the
presence of the ApoEε4 allele) are not modifiable. The
identification of nutritional factors associated with increased
risk of cognitive decline may consequently represent an
opportunity to develop novel risk reduction strategies. Several
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epidemiological studies (2-4) and clinical trials (5-7)) have
reported strong links between nutritional status and cognitive
health in older persons, suggesting that specific nutrients may
play a role of lowering the risk of cognitive decline, especially
in frail elderly people at risk of nutritional deficiencies and
incident AD. These studies were initially focused on specific
deficiencies of micronutrients involved in neuroprotection
and/or regulation of the oxidative status (8-15). For example,
the protective effect of fish oil consumption has been attributed
to its high content of long-chain omega-3 polyunsaturated fatty
acids (PUFA), in particular docosahexaenoic acid (DHA) (16).
Longitudinal and cohort studies also show an association
between diabetes, hyperhomocysteinemia, hypercholes-
terolemia, low intake of n-3 fatty acids and oxidative stress
with the risk of dementia. Nevertheless, evidence is still
controversial, with epidemiologic studies failing to demonstrate
a relationship between omega-3 PUFA intake and risk of
dementia or cognitive decline. The most consistent evidence is
available for longer-chain omega-3 fatty acids (often measured
as fish consumption), with several longitudinal studies showing
an association with reduced risk for cognitive decline (17).
Another example might be provided by results from the Three-
City (3C) study, which analyzed the relationship between fat-
or antioxidant-rich dietary components and the risk of dementia
in older persons. Authors found that the frequent consumption
of fruits, vegetables, fish, and omega-3 rich oils may play a role
at decreasing the risk of dementia, especially in ApoEε4-non
carriers (2). 
Large clinical trials have also been conducted to test the
effects of nutritional supplements on the progression of
cognitive decline.  For example, a multicenter, randomized,
double-blind placebo controlled clinical trial of antioxidants
(600 mg vitamin E, 250 mg vitamin C and 20 mg β-carotene
daily) failed to show any slowing of cognitive decline in the
treatment group (18). Another multi-center trial of
Docosahexaenoic acid (DHA) supplementation in individuals
with mild to moderate AD showed no effect on cognitive or
functional decline (16). Few trials have tested the effect of
nutritional supplementation on the risk of cognitive decline in
non-demented individuals. One example is the PREADVISE
trial, which investigated the effect of anti-oxidants (daily doses
of 400 IU vitamin E/ or placebo and 200µg selenium/or
placebo)  in decreasing the risk of AD among men enrolled in
an even larger prostate cancer prevention study (19) . Ginkgo
biloba extract was also recently investigated as a preventive
treatment for AD (20). Despite failing to meet the primary
outcome of a reduction in the number of subjects converting to
AD, some possible protective effects were observed. These
subtle benefits must be confirmed in the population subgroup
that took gingko biloba extract for at least 4 years (20).
Additional studies have further investigated the effectiveness of
nutrients,  including omega 3 fatty acids, DHA, vitamin E,
vitamin C, and coeznyme Q, using more specific
neuropsychologic measures and CSF biomarkers as outcomes,
with little success (21-23). Two trials that have shown apparent
benefits tested an oral ketogenic compound, AC-1202, in
subjects with probable AD (24) and  a medical food called
Souvenaid®  in subjects with mild AD (25). Souvenaid
contains a specific nutrient combination patented under the
name Fortasyn™ Connect, which is designed to stimulate
synapse formation. 
The possibility that nutritional intervention may protect
against cognitive decline is an inviting prospect and data
supporting a potential effect of dietary patterns are regularly
published. However, long-term, large-scale randomized trials
are still sparse. 
European Food Safety Authority  (EFSA) guidelines for
claims on cognitive function
The European Food Safety Authority’s Panel on Dietetic
Products, Nutrition, and Allergies (NDA) issued a guidance in
2012 regarding scientific requirements to support health claims
related to nervous system function for foods or food
constituents such as vitamins (26). 
The guidance addresses two key issues related to the
substantiation of health claims: First, that health claims should
only be permitted when the food or food constituent is shown to
have a beneficial physiologic effect, and second, that the
studies must have been well designed and executed and carried
out in an appropriate study population; and that outcome
measures utilize established and validated diagnostic tools,
including measures of neural activity as supportive evidence of
a neuropsychological benefit.  A beneficial physiologic effect
in the nervous system is defined as maintenance or
improvement of a psychological, perceptual, psychomotor, or
physiologic regulatory function; or a reduction in a disease risk
factor.   
With respect to the study population, the guidelines
supported studies in well characterized subjects with mild
cognitive decline, with extrapolation to more cognitively
impaired patients considered on a case-by-case basis.  
What is recommended in order to obtain nutrition claims?
The role of public agencies is to formulate guidelines to
support the implementation of public health policies in the
apparently healthy population.  For example, the EFSA was
established to develop procedures and guidelines related to food
safety, and has also issued guidances related to nutrition and
health claims of foods.  Related to the work of the Task Force,
these regulations provide definitions of nutrition references,
based on nutritional requirements in order to evaluate the
relationship of food consumption to age-related metabolic
modifications and the nutrition of elderly people in frailty or
pathological contexts (see Text box). 
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Design of nutritional intervention trials targeting cognitive
decline
Nutritional intervention trials that target cognitive decline
are complicated by the multiple and poorly understood
pathways through which nutrition affects cognition,  the
multiple domains of cognition that may be affected, and
individual differences in the ability to cope with
neuropathology and the influence of cognitive reserve on
coping. Given the heterogeneous manifestations of cognitive
decline and the wide spectrum of underlying
pathophysiological mechanisms, the Task Force recommended
consideration of alternative and adapted designs (e.g.,
multidomain interventions)  (27). The Task Force also
identified other design considerations related to the target
population and sample size, length of the trial, and selection of
endpoints/outcome measures, including biomarkers:  
Target population 
The EFSA guidelines supported studies in well characterized
subjects with mild cognitive decline, indicating that
extrapolation of the results to a larger target group may be
considered on a case-by-case basis.  A number of issues were
identified related to the selection of the study population in
order to facilitate extrapolation.  In selecting a target
population, the study team must take into account the
intervention to be tested, the study design, and the study
outcome. Several target populations may be proposed, each
with specific advantages and limitations:
• The recruitment of pre-frail and frail older persons (defined
according to the phenotype proposed by Fried and
colleagues in the Cardiovascular Health Study (28)) with
cognitive impairment (e.g., CDR equal to 0.5) may represent
an interesting population since frail elders are at increased
risk of having both nutritional deficiencies and dementia. In
fact, the malnutrition component included in the frailty
phenotype (i.e., weight loss) may enhance the possibility of
implementing a nutritional intervention.
• Individuals with Mild Cognitive Impairment (MCI) may be
an interesting target population, although it might be
difficult to recruit these people because an evaluation in a
memory center is usually needed
• PET amyloid positive individuals represent approximately
20 to 30% of older adults aged over 70 years. As they are
thought to be at high risk of developing AD, they could
represent a good target population although PET imaging
would add substantial cost to the study.. 
• Other biomarkers may also be used to select appropriate
study subjects.
• APOEε4 is an important risk factor for AD, and older adults
who are carriers of this allele may represent a good target
population for nutritional studies. Even if not used as an
inclusion criteria, the presence of an APOE4 allele could be
a confounding factor that needs to be taken into account in
balancing study groups.
• Other populations at high risk of cognitive decline may also
represent appropriate subjects, for example those with a
family history of AD. 
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EFSA expectations regarding food/nutritional claims
Characterization of the food (this word encompasses any situation:
a food, a part of a food, an ingredient, an extract, a purified natural or
synthetic molecule); this characterization should be done in relation
to the claim, not in an absolute way: thus it may be enough to have
standardized the food for something which is considered as the active
part for the claimed effect, taking into account as appropriate the
content of other elements for which approved claims exist. This
characterization is needed in order to check that any provided study
for substantiation can actually apply to the proposed food. In case of
positive outcome for the claim substantiation, this characterization
will also be important for defining the conditions of use of the claim
and, ultimately, will allow the possibility of control for control
authorities. The applicant can choose to apply for a product-specific
claim, the product being characterized by e.g. a fixed combination of
nutrients and/or a specific manufacturing  process: the claim
substantiation should be based on studies performed with this
specific product; studies performed with individual nutrients or other
foods claimed to be similar can only be used as supportive evidence. 
Characterization of the target population for the claim, leading to
the issue of the possible difference between the target population and
the study population. Given the constant interdiction of medicinal or
therapeutic claims for foods (including dietary supplements), the
target population should be an apparently healthy population, even if
this population is at increased risk of a specific disease or affected by
functional impairment. From the example of cholesterol-lowering
food due to phytosterol content, it clearly appears that it is a matter of
wording at the basis of the classification: food containing phytosterol
targets people who want to maintain or reduce their blood cholesterol
and do not explicitly target people with hypercholesterolemia
(requiring a clinical diagnosis). 
At the preliminary approach, the absence of interference (at the
mechanistic level) between the drug and the food allows the inclusion
of subjects using drugs in the study group. However, it would be safe
to balance the groups on this aspect in order to avoid/limit any bias or
uncertainty from this possible confounding factor. In any case, there
is a continuum between healthy people and overtly diseased people
and placing the boundary may always be questioned. 
A third issue will have to be considered in the future, and at present
can only be mentioned: in order to support a claim, the food should
comply with a nutrient profile, according to article 4 of the claim
regulation. Such point is aimed at avoiding that a food with a high
content of potentially deleterious nutrients (e.g. fat, saturated fat,
sugars, trans fatty acid, salt) may be promoted by simply adding 15
% of the RDA of specific vitamins or minerals. 
The regulation does not contain the possibility of exemptions for
health claims and risk reduction claims. Since, to date, nutrient
profiles are not yet defined, this aspect leaves some uncertainty when
considering multi-nutrient foods.
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Sample size 
Sample size calculations must be conducted for the primary
outcome of the trial in order to guarantee its optimal design.
Large sample sizes are likely to be needed given the
heterogeneity of the decline observed across older persons        
Length of the trial
Symptomatic trials must be between 6 and 12 months in
duration in order to be able to observe a decline in the placebo
group. Disease modifying trials must be at least 18 months to
really be able to have an effect on the disease course. (29-33).
Preventive trials may require 3 to 5 years of follow-up.
Although long-term randomized controlled trials (RCTs) are
the ideal approach, in many cases the barriers to implementing
such studies may make them unrealistic. For this reason, RCTs
might aim to identify individuals at high risk of cognitive
decline to make trials more efficient and economical. 
Other issues to consider in planning the length of a trial
include:
• The intensity, duration, and timing of the exposure, should
be taken into account. Exposures may be more influential
and interventions more effective during specific times and in
the presence of specific conditions.
• Given the usual long subclinical, prodromal period of
neurodegenerative diseases, trials need to consider extended
periods of follow-up. 
Endpoints/Outcomes 
The choice of outcome measures depends on the expected
effects of the intervention. Since multidomain interventions
may be necessary, multiple outcome measures may also be
needed. The choice of outcome should also be adapted to the
population under study. Studies should test the hypothesized
effects of a nutritional intervention on appropriate outcome
measures (i.e. cognition) by using validated, reliable and
accurate psychometric tests, as well as markers of specific
pathways. 
Some domains (such as memory) may be considered as more
“clinically relevant”, and as such, particularly important.
Subjective memory complaint may represent a key feature for
preventive trials on cognitive decline because associated with
an increased risk for dementia. Moreover, this symptom may be
easily detected by healthcare professionals (facilitating the
potential participants recruitment), and has already been used in
large trials. A good test of episodic memory is the Free and
Cued Selective Reminding Test (FCSRT), which has shown to
be predictive of memory changes in AD (34). Batteries of tests
covering multiple cognitive domains have been developed and
validated over the years (e.g., the Neuropsychological Test
Battery (29) or the Clinician Dementia Rating scale (30). 
Biomarkers (both CSF and imaging) may also be used as
secondary outcome measures, and may be measured only in a
subgroup of the total population (31-33, 35, 36). They may be
especially useful when anticipating a disease modifying effect
or in preventive trials.
The modification of a risk factor for a disease, rather than
the direct action on the disease itself may also be the subject of
a claim. In the absence of a well-established risk factor for
dementia or cognitive decline (such as the high level of LDL-
cholesterol or blood pressure which are well established for
cardiovascular disease), there should be a demonstration of
both the reduction of the risk factor and of the disease itself.
Other important considerations when selecting outcome
measures include:
• tests (especially those used in prevention trials) should be
sufficiently sensitive to changes. 
• For the EFSA, it is the responsibility of the applicant to
demonstrate that the test chosen has been validated for the
purpose (i.e. cognitive decline) in the specific population. 
• In the statistical treatment of the results, the consideration of
multiple outcomes should be done using appropriate
statistical corrections.
• Other factors that may need to be assessed as covariates
include nutritional status, physical exercise and cognitive
activity. 
Conclusion 
Nutrition is a domain that should be more fully explored as a
determinant of cognitive impairment in the older persons.
Moreover, links between nutrition and physical and cognitive
frailty make this an area of particular interest for nutrition
intervention (37-39). 
The efficacy of nutritional interventions on cognition should
be tested using recommendations that mirror those already
established for the design of pharmacological trials.  For
example, the selection of a target population, study design, and
the study outcome for appropriate the tested intervention is very
important. With regard to the study design, large sample sizes
will most likely be needed. For symptomatic treatments, trials
of between 6 and 12 months in duration will be required in
order to detect a decline in the placebo group, while preventive
trials may require 3 to 5 years of follow-up. 
The EFSA reports that of 2,927 consolidated health claims
for different ingredients examined, only 241 passed muster.
This high rejection rate in an industry that has lobbied against
legislation requiring stricter approval standards and costly
quality control (40) prompted the members of this Task Force
to propose ambitious and robust trials aimed at obtaining
similar success to those obtained in the past for cardiovascular
diseases and osteoporosis.
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